Close Menu


Exact Sciences discussed newly released data and its plans for Cologuard, while Luminex provided details about its warning letter from the FDA.

Some insiders emphasize the importance of doing rapid turnaround testing of asymptomatic people, while others contend lab tests ought to be the modality of choice.

The company's goal is to help laboratories and smaller diagnostic firms accelerate test development and provide end-to-end test design assistance.

The revenue increase was driven by significant growth in the conglomerate's life sciences segment.

News items for the in vitro diagnostics industry for the week of Oct. 5, 2020

The company said that its Access Interleukin-6 assay is designed to assist physicians in the identification of severe inflammatory response in COVID-19 patients.

The company said it intends to use proceeds for general corporate purposes, including working capital and refinancing of outstanding indebtedness.

News items for in vitro diagnostics industry for the week of Sept. 14, 2020.

While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.